Commercial agreement signed with KSF Acquisition

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Commercial Agreement signed with KSF Acquisition UK Limited

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a commercial agreement with KSF Acquisition UK Limited ('KSF). The agreement provides funding to assess the benefits of using Optibiotix's SlimBiome® weight management product alongside KSF's weight management dietary programme and provides KSF with an option to commercialise SlimBiome®.

OptiBiotix's SlimBiome® contains ingredients clinically proven to reduce weight formulated by world experts to act at different parts of the body in three different ways to affect appetite, metabolism, and energy harvest.

KSF's established brand with its scientifically proven weight management programme uses meal replacement products to support weight loss. 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of this commercial agreement with KSF, whose dietary programme is a trusted and well recognised global brand in weight management. This agreement brings together OptiBiotix's novel science with KSF's industry expertise, product range, and market reach to access a market estimated globally to be worth $622bn in 2015. OptiBiotix continues to make strong commercial progress across all it platforms consistent with its strategy of creating multiple product and partnering opportunities for large global markets with an unmet need."

About OptiBiotix Health PLC - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About KSF ACQUISITION UK LIMITED (KSF) www.slimfast.co.uk 

KSF Acquisition UK Ltd. is an investee of Kainos Capital, with a responsibility for the SlimFast brand in the UK, Ireland and Germany. Kainos Capital acquired the SlimFast brand from Unilever in 2014. SlimFast is a scientifically proven weight loss plan with a branded range of shakes, bars and snacks. The global market for slimming and dietary products is estimated at $622bn.